quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:50:26·118d
ANALYSTRating
Inhibikase Therapeutics Inc. logo

H.C. Wainwright initiated coverage on Inhibikase Therapeutics with a new price target

IKT· Inhibikase Therapeutics Inc.
Health Care
Original source

Companies

  • IKT
    Inhibikase Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 4UpdateLadenburg Thalmann$4.00
  • Jan 21UpdateBofA Securities$6.00
  • Dec 26UpdateH.C. Wainwright$8.00
  • Dec 11UpdateCantor Fitzgerald$4.00
  • Feb 12UpdateH.C. Wainwright-
  • Jul 15UpdateJonesTrading$12.00

Related

  • SEC3d
    SEC Form PRE 14A filed by Inhibikase Therapeutics Inc.
  • SEC16d
    Inhibikase Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • PR16d
    Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
  • PR20d
    Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC28d
    SEC Form S-8 filed by Inhibikase Therapeutics Inc.
  • SEC28d
    SEC Form 10-K filed by Inhibikase Therapeutics Inc.
  • SEC28d
    SEC Form 8-K filed by Inhibikase Therapeutics Inc.
  • PR28d
    Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022